Drug intelligence / Profile preview

RD05

Development stage: Preclinical
Lead developer: Tectonic Therapeutics
Modality: Small Molecules

Overview

RD05 is a small molecule drug candidate currently in the preclinical stage of development by NucMito Pharmaceuticals (藤济医药). While specific details regarding its molecular target and primary therapeutic indication have not been fully disclosed in public pipeline records, it is part of a portfolio that focuses on nuclear receptor-related therapies and mitochondrial function regulation. The developer, NucMito Pharmaceuticals, specializes in targeting the Retinoid X Receptor alpha (RXRα) and its variants for applications in oncology and metabolic diseases such as non-alcoholic steatohepatitis (NASH).

Targets

RYR2 (Ryanodine receptor 2)

Beyond the preview

Go deeper on RD05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD05.

Explore the full profile